UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-K/A Amendment No.1   (Mark One) ☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR  ☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from
 to Commission File Number 001-38360   Solid Biosciences Inc. (Exact name of Registrant as specified in its Charter)    Delaware

90-0943402(State or other jurisdiction of
incorporation or organization)

(I.R.S. EmployerIdentification No.)141 Portland Street, Fifth Floor
Cambridge, MA

02139(Address of principal executive offices)

(Zip Code) Registrants telephone number, including area code:
(617) 337-4680   Securities
registered pursuant to Section 12(b) of the Act:  Title of each class

Trading
Symbol

Name of exchange
on which registeredCommon Stock $0.001 par value per share

SLDB

The Nasdaq Global Select Market Securities registered pursuant to Section 12(g) of the Act: None (Title of class)   Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.    YES  ☐    NO  ☒ Indicate by check mark if the registrant is not required
to file reports pursuant to Section 13 or Section 15(d) of the Act.    YES  ☐    NO  ☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.    YES  ☒    NO  ☐ Indicate by check mark whether the Registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for
such shorter period that the Registrant was required to submit such files).    YES  ☒    NO  ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.  Large accelerated filer

☐

Accelerated filer

☒Non-accelerated filer

☐

Smaller reporting company

☒Emerging growth company

☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the
Act).    YES  ☐    NO  ☒ As of June 28, 2019, the last business day of the
Registrants most recently completed second fiscal quarter, the aggregate market value of the Registrants common stock held by non-affiliates was $100.9 million, based on the last reported sale
price of such stock on the Nasdaq Global Select Market as of such date. The number of shares of Registrants common stock outstanding as of
February 15, 2020 was 46,068,049.




---

EXPLANATORY NOTE On March 12, 2020, Solid Biosciences Inc. (the Company) filed its Annual Report on Form 10-K for the
fiscal year ended December 31, 2019 (the Original Form 10-K). This Amendment No. 1 (the Amendment) amends the Original Form 10-K
solely to correct a typographical error in Exhibit 23.1, Consent of Independent Registered Public Accounting Firm. The Exhibit 23.1 included in the Original Form 10-K identified the report date as March 10, 2020 whereas the appropriate
date is March 12, 2020. A new Exhibit 23.1 with the correction is filed as Exhibit 23.1 attached hereto. This Amendment speaks as of the
original filing date and does not reflect events occurring after the filing of the Original Form 10-K. No revisions are being made to the Companys financial statements or any other disclosure contained in the Original Form 10-K. This
Amendment is an exhibit-only filing. Except for Exhibit 23.1, this Amendment does not otherwise update any exhibits as originally filed or previously amended. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the Exchange Act), new certifications by the
Companys principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. As no financial statements have been included in this
Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. The Company is
not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment.




---

PART IV  Item 15.
Exhibits, Financial Statement Schedules  Exhibit
Number

Description23.1*

Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.31.1*

Certification of Chief Executive Officer of the Registrant Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2*

Certification of Chief Financial Officer of the Registrant Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.  *
Filed herewith.




---

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused
this Report to be signed on its behalf by the undersigned, thereunto duly authorized.  SOLID BIOSCIENCES INC.Date: March 13, 2020



By:

/s/ Ilan GanotIlan Ganot
President, Chief Executive Officer and Director
(Principal Executive Officer)